Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Centessa Pharmaceuticals (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on developing transformational medicines, has announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The company's management team will engage in a fireside chat on Tuesday, September 9th at 4:50 PM ET.
Investors and interested parties can access the live audio webcast and archived recording through the "Events & Presentations" section on Centessa's investor relations website.
Centessa Pharmaceuticals (Nasdaq: CNTA), azienda biofarmaceutica in fase clinica dedicata allo sviluppo di terapie rivoluzionarie, ha annunciato la sua partecipazione al Morgan Stanley 23rd Annual Global Healthcare Conference a New York. Il team dirigente dell'azienda terrà un intervento informale (fireside chat) martedì 9 settembre alle 16:50 ET.
Investitori e altri interessati possono seguire la diretta audio e rivedere la registrazione archiviata nella sezione "Events & Presentations" del sito per gli investitori di Centessa.
Centessa Pharmaceuticals (Nasdaq: CNTA), compañía farmacéutica en fase clínica centrada en desarrollar medicamentos transformadores, ha anunciado su participación en la Morgan Stanley 23rd Annual Global Healthcare Conference en Nueva York. El equipo directivo ofrecerá un encuentro informal (fireside chat) el martes 9 de septiembre a las 4:50 PM ET.
Los inversores y el público interesado pueden acceder a la retransmisión de audio en directo y a la grabación archivada en la sección "Events & Presentations" del sitio web de relaciones con inversores de Centessa.
Centessa Pharmaceuticals (Nasdaq: CNTA)는 혁신적 의약품 개발에 주력하는 임상 단계 제약사로, 뉴욕에서 열리는 Morgan Stanley 23rd Annual Global Healthcare Conference에 참가한다고 발표했습니다. 회사 경영진은 9월 9일 화요일 오후 4시 50분(동부시간)에 파이어사이드 채팅에 참여합니다.
투자자 및 관심 있는 분들은 Centessa 투자자관계 웹사이트의 "Events & Presentations" 섹션에서 라이브 오디오 웹캐스트와 아카이브 녹음을 이용하실 수 있습니다.
Centessa Pharmaceuticals (Nasdaq: CNTA), société pharmaceutique en phase clinique dédiée au développement de médicaments transformateurs, a annoncé sa participation à la Morgan Stanley 23rd Annual Global Healthcare Conference à New York. L'équipe dirigeante tiendra un échange informel (fireside chat) mardi 9 septembre à 16h50 ET.
Les investisseurs et les personnes intéressées peuvent accéder à la diffusion audio en direct et à l'enregistrement archivé dans la rubrique "Events & Presentations" du site relations investisseurs de Centessa.
Centessa Pharmaceuticals (Nasdaq: CNTA), ein pharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung bahnbrechender Medikamente konzentriert, hat seine Teilnahme an der Morgan Stanley 23rd Annual Global Healthcare Conference in New York angekündigt. Das Management wird an einem Fireside-Chat am Dienstag, den 9. September um 16:50 Uhr ET teilnehmen.
Investoren und Interessierte können den Live-Audio-Webcast sowie die aufgezeichnete Archivversion über den Bereich "Events & Presentations" auf Centessas Investor-Relations-Website abrufen.
- None.
- None.
BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. A fireside chat is scheduled for Tuesday, September 9th at 4:50 PM ET.
The live audio webcast of this event, as well as an archived recording, will be available under the “Events & Presentations” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals, plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients. We are pioneering a new class of potential therapies within our orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, and fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. For more information, visit www.centessa.com, which does not form part of this release.
Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com
FAQ
When is Centessa Pharmaceuticals (CNTA) presenting at the Morgan Stanley Healthcare Conference 2025?
How can investors access Centessa Pharmaceuticals' (CNTA) Morgan Stanley conference presentation?
What type of company is Centessa Pharmaceuticals (CNTA)?
Where is the Morgan Stanley Healthcare Conference 2025 being held?
